SCHEMBL20119938

SCHEMBL20119938

CNCc1nc2c(NCc3ccco3)nc(Cl)nc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.51
KMT2A Q03164 5/20 0.44
HSD17B10 Q99714 3/20 0.44
MEN1 O00255 2/20 0.44
PKM P14618 1/20 0.44
LMNA P02545 6/20 0.43
MAPT P10636 4/20 0.43
MAPK1 P28482 4/20 0.43
HTT P42858 4/20 0.43
KDM4E B2RXH2 4/20 0.43
BLM P54132 1/20 0.43
EGFR P00533 1/20 0.42
RECQL P46063 1/20 0.41
HPGD P15428 4/20 0.39
ALDH1A1 P00352 3/20 0.39
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119744 0.90 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AHSD17B10MEN1PKM
SCHEMBL20119584 0.87 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AHSD17B10MEN1PKM
SCHEMBL22403783 0.86 SMN1; SMN2 (0.49) SMN1; SMN2KMT2AHSD17B10MEN1PKM
SCHEMBL25873860 0.85 SMN1; SMN2 (0.50) SMN1; SMN2KMT2AHSD17B10MEN1PKM
SCHEMBL20119685 0.85 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AHSD17B10MEN1PKM
SCHEMBL20119700 0.84 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AHSD17B10MEN1PKM
SCHEMBL20119969 0.84 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AHSD17B10MEN1PKM
SCHEMBL20119901 0.82 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AHSD17B10MEN1PKM
SCHEMBL20119577 0.82 SMN1; SMN2 (0.49) SMN1; SMN2KMT2AHSD17B10MEN1PKM
SCHEMBL20119668 0.81 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AHSD17B10MEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HSD17B10 1293/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HSD17B10 1293/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HSD17B10 1293/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HSD17B10 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.